[1]
B., V. 2022. A REVIEW ON THE DEVELOPMENT OF FAVIPRAVIR AGAINST SARS COV 2 INFECTION. International Journal of Current Pharmaceutical Research. 14, 2 (Mar. 2022), 11–14. DOI:https://doi.org/10.22159/ijcpr.2022v14i2.1957.